Novo Nordisk’s ziltivekimab stumbles again on pair of Phase III terminations

Novo Nordisk will stop two ziltivekimab trials early, though it will continue the a study on drug as an acute treatment post-heart failure. While two trials in heart failure and inflammation will stop early, the ongoing study evaluating ziltivekimab as an acute treatment post-heart failure will continue. The HERMES and ATHENA trials will stop due to a data monitoring committee’s recommendation. Credit: Below the Sky / Shutterstock.com. Novo Nordisk has opted to prematurely end two Phase III trials of its inflammation-targeting candidate, ziltivekimab, after the drug was deemed unlikely to meet its goals in either study. In a statement to…

Source: Clinical Trials Arena